
In the past 40 years, little progress has been made toward finding an effective treatments for adrenal cancer, with only one drug called Mitotane (a derivative of DDT) being approved in the last 40 years, it is obvious that new drugs need to be tested. Adrenocortical Carcinoma affects only one or two people in a 1.7 million people and is often difficult to collect enough adrenal tumors to analyze, which is why the TGen study is so significant. With you support we can find new treatments for this devastating and rare form of adrenal cancer.
THANK YOU FOR YOUR SUPPORT

TGen News
TGen Clinical TrialsThe Adrenocortical
Cancer
Patient Survey has been set up because many ACC survivors and their
families
have requested more information on what fellow ACC survivors are
experiencing.
The information you enter will be collected and shared with others
taking the
survey, in order to help them better deal with this rare disease. The
information in the survey will also help inform future research efforts
for ACC.
The survey is detailed and
includes questions relating to personal information like health history,
but
the results will be anonymous. AT NO TIME WILL YOU BE ASKED TO PROVIDE
YOUR
NAME, IDENTIFYING INFORMATION or CONTACT INFORMATION. Reports
available to you and researchers
will include only summaries of the data collected and no individual
surveys
will be available.
If you would like to participate in the survey, please click here.